Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Last updated: April 13, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Overall Status: Active - Recruiting

Phase

1

Condition

Carcinoma

Treatment

Iodine-124

PET/CT Scan

Clinical Study ID

NCT03647358
18-253
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults with thyroid carcinoma confirmed by pathology.

  • Adult thyroid carcinoma patients who have undergone total thyroidectomy

  • Adult thyroid carcinoma patients have metastatic disease or suspicion for metastaticdisease, or are under a protocol intended to explore re-induction therapy for 131Iuptake, and are about to undergo Thyrogen-assisted dosimetry, unlessThyrogen-assisted dosimetry is not required per standard of care.

  • The patient and physician are planning to administer 131I for therapy if persistentradioiodine-avid metastases are present.

  • All subjects must have measurable disease, documented within the previous six monthsby ultrasonography (US), MRI, FDG PET/CT, or CT scanning.

Exclusion

Exclusion Criteria:

  • Age less than 18 years.

  • Patients who are pregnant.

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Iodine-124
Phase: 1
Study Start date:
August 21, 2018
Estimated Completion Date:
August 31, 2027

Connect with a study center

  • Memorial Sloan Kettering Cancer Center

    New York, New York 10065
    United States

    Active - Recruiting

  • Weill Cornell Medical Center

    New York, New York 10065
    United States

    Site Not Available

  • Memorial Sloan Kettering Cancer Center

    New York 5128581, New York 5128638 10065
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.